

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)



(10) International Publication Number
WO 2022/241174 A1

(51) International Patent Classification:

C07D 401/10 (2006.01) *A61P 37/00* (2006.01)
C07D 401/14 (2006.01) *A61K 31/501* (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2022/029117

(22) International Filing Date:

13 May 2022 (13.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/188,498 14 May 2021 (14.05.2021) US
63/318,508 10 March 2022 (10.03.2022) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**

[US/US]; Route 206 and Province line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **SPERGEL, Steven H.**; c/o Bristol-Myers

Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **MOSLIN, Ryan M.**; c/
o Bristol-Myers Squibb Company, Route 206 and Province
Line Road, Princeton, New Jersey 08543 (US). **MERTZ-**
MAN, Michael Edward; c/o Bristol-Myers Squibb Com-
pany, Route 206 and Province Line Road, Princeton, New
Jersey 08543 (US).

(74) Agent: **KORSEN, Elliott et al.**; Bristol-Myers Squibb

Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every


kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SUBSTITUTED HETEROCYCLIC COMPOUNDS

(57) Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN α , by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.



I

WO 2022/241174 A1